Establishment of a circRNA-regulated E3 ubiquitin ligase signature and nomogram to predict immunotherapeutic efficacy and prognosis in hepatocellular carcinoma

被引:0
|
作者
Wu, Gefeng [1 ,2 ]
Zhang, Jiahao [1 ,2 ]
Peng, Rui [1 ]
Cao, Jun [1 ]
Tu, Daoyuan [1 ]
Zhou, Jie [1 ]
Su, Bingbing [1 ]
Jin, Shengjie [1 ]
Jiang, Guoqing [1 ]
Zhang, Chi [1 ]
Bai, Dousheng [1 ]
机构
[1] Yangzhou Univ, Clin Med Coll, Dept Hepatobiliary Surg, 98 West Nantong Rd, Yangzhou 225000, Jiangsu, Peoples R China
[2] Dalian Med Univ, Dalian 116000, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; CircRNA; E3 ubiquitin ligase signature; Nomogram; Immune and prognosis; PROTEIN; CELLS; PROLIFERATION; REVEAL; MODELS; ROLES;
D O I
10.1186/s40001-024-01893-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Hepatocellular carcinoma (HCC) is a common type of malignant tumor where the prognosis is dismal. Circular RNA (CircRNA) is a novel RNA that regulates downstream gene transcription and translation to influence the progression of HCC. However, the regulatory relationship that exists between E3 ligases, which is a class of post-translational modifying proteins, and circRNA remains unclear.Methods Based on the E3 ubiquitin ligase in the competitive endogenous RNA (ceRNA) network, a circRNA-regulated E3 ubiquitin ligase signature (CRE3UL) was developed. A CRE3UL signature was created using the least absolute shrinkage and selection operator (Lasso) and Cox regression analysis and merged it with clinicopathologic characteristics to generate a nomogram for prognosis prediction. The pRRophetic algorithm was utilized and immunological checkpoints were analyzed to compare the responses of patients in the high-risk group (HRG) and low-risk group (LRG) to targeted therapy and immunotherapy. Finally, experimental research will further elucidate the relationship between E3 ubiquitin ligase signature and HCC.Results HRG patients were found to have a worse prognosis than LRG patients. Furthermore, significant variations in prognosis were observed among different subgroups based on various clinical characteristics. The CRE3UL signature was identified as being an independent prognostic indicator. The nomogram that combined clinical characteristics and the CRE3UL signature was found to accurately predict the prognosis of HCC patients and demonstrated greater clinical utility than the current TNM staging approach. According to anticancer medication sensitivity predictions, the tumors of HRG patients were more responsive to gefitinib and nilotinib. From immune-checkpoint markers analysis, immunotherapy was identified as being more probable to assist those in the HRG.Conclusions We found a significant correlation between the CRE3UL signature and the tumor microenvironment, enabling precise prognosis prediction for HCC patients. Additionally, a nomogram was developed that performs well in predicting the overall survival (OS) of HCC patients. This provides valuable guidance for clinicians in devising specific personalized treatment strategies.
引用
收藏
页数:21
相关论文
共 45 条
  • [1] Strategic advancement of E3 ubiquitin ligase in the management of hepatocellular carcinoma
    Miao, Yangyang
    Wang, Shunyi
    Zhang, Jiahao
    Liu, Huanxiang
    Zhang, Chi
    Jin, Shengjie
    Bai, Dousheng
    MEDICAL ONCOLOGY, 2024, 41 (07)
  • [2] Role of the E3 Ubiquitin Ligase TRIM4 in Predicting the Prognosis of Hepatocellular Carcinoma
    Dong, Zhao-Ru
    Zhou, Wei
    Sun, Dong
    Yan, Yu-Chuan
    Yang, Chun-Cheng
    Yang, Ya-Fei
    Li, Hai-Chao
    Zhi, Xu-Ting
    Li, Tao
    JOURNAL OF CANCER, 2020, 11 (14): : 4007 - 4014
  • [3] Construction of an anoikis-related prognostic signature to predict immunotherapeutic response and prognosis in hepatocellular carcinoma
    Xiong, Chen
    Pan, Guoqiang
    Wang, Hanchao
    Meng, Guangxiao
    Yan, Lunjie
    Li, Ruizhe
    Yan, Yuchuan
    Yang, Yafei
    Zhang, Xiao
    Yang, Chuncheng
    Dong, Zhaoru
    Li, Tao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (18) : 16869 - 16884
  • [4] Innovative signature establishment using lymphangiogenesis-related lncRNA pairs to predict prognosis of hepatocellular carcinoma
    Cao, Jincheng
    Xu, Yanni
    Liu, Xiaodi
    Cai, Yan
    Luo, Baoming
    HELIYON, 2022, 8 (08)
  • [5] Construction of an anoikis‒related prognostic signature to predict immunotherapeutic response and prognosis in hepatocellular carcinoma
    Chen Xiong
    Guoqiang Pan
    Hanchao Wang
    Guangxiao Meng
    Lunjie Yan
    Ruizhe Li
    Yuchuan Yan
    Yafei Yang
    Xiao Zhang
    Chuncheng Yang
    Zhaoru Dong
    Tao Li
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16869 - 16884
  • [6] E3 Ubiquitin Ligase Siah-1 is Down-regulated and Fails to Target Natural HBx Truncates for Degradation in Hepatocellular Carcinoma
    Zhao, Jing
    Wu, Jing
    Cai, Hao
    Wang, Dan
    Yu, Long
    Zhang, Wen-Hong
    JOURNAL OF CANCER, 2016, 7 (04): : 418 - 426
  • [7] Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis
    Ji, Feiyang
    Zhou, Menghao
    Sun, Zeyu
    Jiang, Zhengyi
    Zhu, Huihui
    Xie, Zhongyang
    Ouyang, Xiaoxi
    Zhang, Lingjian
    Li, Lanjuan
    CANCER COMMUNICATIONS, 2021, 41 (10) : 1007 - 1023
  • [8] The E3 ubiquitin ligase MG53 inhibits hepatocellular carcinoma by targeting RAC1 signaling
    Ma, Xiaomin
    Ma, Xiaoxiao
    Zhu, Lihui
    Zhao, Yunxue
    Chen, Mengmeng
    Li, Tao
    Lin, Yueke
    Ma, Dapeng
    Sun, Caiyu
    Han, Lihui
    ONCOGENESIS, 2022, 11 (01)
  • [9] The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein
    Zhu, Lihui
    Qin, Chengyong
    Li, Tao
    Ma, Xiaomin
    Qiu, Yumin
    Lin, Yueke
    Ma, Dapeng
    Qin, Zhenzhi
    Sun, Caiyu
    Shen, Xuecheng
    Zhao, Yunxue
    Han, Lihui
    CELL DEATH AND DIFFERENTIATION, 2020, 27 (06) : 1819 - 1831
  • [10] The E3 Ubiquitin Ligase Cbl-b Predicts Favorable Prognosis in Breast Cancer
    Liu, Xiuming
    Teng, Yuee
    Wu, Xin
    Li, Zhi
    Bao, Bowen
    Liu, Yunpeng
    Qu, Xiujuan
    Zhang, Lingyun
    FRONTIERS IN ONCOLOGY, 2020, 10